In a phase I trial of the PARP inhibitor olaparib (formerly AZD2281), significant responses were observed only in BRCA1-mutant and BRCA2-mutant cancers, with no responses in tumors wild-type for BRCA (Fong et al., 2009). This evidence concerns the gene BRCA2 and cancer.